started · updated
Oncohematology innovation improves patient prognoses
Advancements in molecular knowledge, targeted therapies, bispecific antibodies, and cell therapies are significantly improving the prognosis for patients with oncohematological diseases, such as certain leukemias, multiple myeloma, and myelodysplastic syndromes.
During the III National Meeting of Oncohematological Disease Associations held in Madrid, stakeholders discussed the challenge of translating scientific innovation into patient-centered care. The event brought together patients, families, and healthcare professionals to analyze progress in lymphomas and leukemias.
In a separate clinical focus, experts from Servier and the Hospital Internacional de Colombia are highlighting the urgency of addressing Acute Myeloid Leukemia (AML). As part of Hematological Cancer Awareness Month in September, professionals are emphasizing the need for early detection and specialized multidisciplinary care for this rapidly progressing blood cancer.
Entities
Grupo Cero · Hospital Internacional de Colombia · Madrid · Servier
Claims
What the coverage asserts, and how many sources carry each claim.
- [○ 1 SOURCE] Acute myeloid leukemia (AML) is a rapidly progressing type of blood cancer originating in the bone marrow. www.hsbnoticias.com
- [○ 1 SOURCE] Experts from Servier and the Hospital Internacional de Colombia are working to increase awareness of AML during Hematological Cancer Awareness Month in September. www.hsbnoticias.com
- [○ 1 SOURCE] Molecular knowledge, targeted therapies, bispecific antibodies, and cell therapies are improving prognoses for oncohematological diseases. www.immedicohospitalario.es
- [○ 1 SOURCE] Grupo Cero held the III National Meeting of Oncohematological Disease Associations in Madrid from September 4 to 6. www.immedicohospitalario.es